Chetan Naik, MD
Pulmonary Disease · Dallas, TXNPI 1952562324
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Actelion Pharmaceuticals US, Inc. accounts for 62.3% of it on its own, with 10 other manufacturers making up the rest. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $325.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$15K
- United Therapeutics Corporation$9K
- Merck$273
- Penumbra, Inc.$113
- Abbott$91
- Boehringer Ingelheim$47
- plus $98 from 5 others
Across 47 payments — averaging $13,911 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$459K
- Insmed, Inc.$110K
- United Therapeutics Corporation$85K
What the payments were for
- Consulting fees$6,55027%
- Speaking & faculty fees$12,87053%
- Travel & lodging$1,1375%
- Food & beverage$3,70415%
- Education$1761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 41 | $15,227 |
| United Therapeutics Corporation | 18 | $8,587 |
| Merck | 7 | $273 |
| Penumbra, Inc. | 1 | $113 |
| Abbott | 1 | $91 |
| Boehringer Ingelheim | 1 | $47 |
| AbbVie | 2 | $27 |
| Insmed, Inc. | 1 | $25 |
| Gilead | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$13,846
- OPSUMIT$11,432
- TYVASO$8,046
- REMODULIN$152
- Indigo System$113
How this compares
$24,437 in reported general payments places this provider in the 90th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 253 | $3,189,919 |
| Tyvaso DpiTreprostinil | 76 | $1,866,416 |
| UptraviSelexipag | 52 | $1,291,272 |
| AdempasRiociguat | 82 | $1,121,179 |
| OfevNintedanib Esylate | 48 | $657,264 |
| Ambrisentan | 66 | $100,722 |
| Tadalafil | 169 | $89,550 |
| EliquisApixaban | 31 | $22,193 |
| Sildenafil Citrate | 79 | $19,638 |
| Mycophenolate Mofetil | 26 | $3,996 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,666 |
| Bumetanide | 52 | $3,547 |
| Itraconazole | 15 | $1,806 |
| Potassium Chloride | 49 | $1,452 |
| Furosemide | 148 | $1,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $15,227 | $4,481,191305 claims |
| Boehringer IngelheimOfev | $47 | $657,26448 claims |
| PfizerEliquis | $14 | $22,19331 claims |
| AstraZenecaSymbicort | $15 | $3,66612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Dallas
- Yolanda MagetoDallas$239K
- Mark MillardDallas$192K
- Raksha JainDallas$153K
- Sonja BartolomeDallas$75K
- Kelly ChinDallas$72K
- Fernando TorresDallas$61K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.